Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mindbio Therapeutics Corp. ( (TSE:MBIO) ) has shared an announcement.
MindBio Therapeutics Corp. has enrolled its 85th participant in a Phase 2B clinical trial for its proprietary LSD formulation, MB22001, aimed at treating Major Depressive Disorder. This trial marks a significant milestone in the company’s mission to transform mental health treatment by offering a practical, scalable alternative to clinic-based therapies. MindBio is also conducting trials for cancer-related existential distress and plans to start a trial for PMS and PMDD, showcasing the versatility of its therapeutic platform. The company’s recent launch of the Booze AI app further highlights its commitment to commercializing its intellectual property and expanding its market presence.
More about Mindbio Therapeutics Corp.
MindBio Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing novel psychedelic-based medicines for mental health disorders. The company is pioneering the use of microdosing to provide safe, effective, and scalable treatments for conditions such as depression and anxiety, with a mission to improve global mental health outcomes through innovative, evidence-based treatments that are accessible and affordable.
Average Trading Volume: 221,011
Technical Sentiment Signal: Sell
See more data about MBIO stock on TipRanks’ Stock Analysis page.